Literature DB >> 24569775

The role of PAX5 and C/EBP α/β in atypical non-Langerhans cell histiocytic tumor post acute lymphoblastic leukemia.

F Pagni1, G Fazio2, S Zannella1, M Spinelli3, C De Angelis3, C Cusi1, F Crosti4, L Corral5, C Bugarin5, A Biondi3, G Cazzaniga5, G Isimbaldi1, G Cattoretti1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24569775     DOI： 10.1038/leu.2014.87

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Biphenotypic B-lymphoid/myeloid cells expressing low levels of Pax5: potential targets of BAL development.

Authors:  Szandor Simmons; Marko Knoll; Christopher Drewell; Ingrid Wolf; Hans-Joachim Mollenkopf; Corinne Bouquet; Fritz Melchers
Journal:  Blood       Date:  2012-08-27       Impact factor: 22.113

3.  Diverse and heritable lineage imprinting of early haematopoietic progenitors.

Authors:  Shalin H Naik; Leïla Perié; Erwin Swart; Carmen Gerlach; Nienke van Rooij; Rob J de Boer; Ton N Schumacher
Journal:  Nature       Date:  2013-04-03       Impact factor: 49.962

Review 4.  Differentiation-linked leukemogenesis in lymphocytes.

Authors:  M F Greaves
Journal:  Science       Date:  1986-11-07       Impact factor: 47.728

5.  C/EBPα induces highly efficient macrophage transdifferentiation of B lymphoma and leukemia cell lines and impairs their tumorigenicity.

Authors:  Francesca Rapino; Eloy F Robles; Jose A Richter-Larrea; Eric M Kallin; Jose A Martinez-Climent; Thomas Graf
Journal:  Cell Rep       Date:  2013-03-28       Impact factor: 9.423

6.  Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study.

Authors:  Valentino Conter; Claus R Bartram; Maria Grazia Valsecchi; André Schrauder; Renate Panzer-Grümayer; Anja Möricke; Maurizio Aricò; Martin Zimmermann; Georg Mann; Giulio De Rossi; Martin Stanulla; Franco Locatelli; Giuseppe Basso; Felix Niggli; Elena Barisone; Günter Henze; Wolf-Dieter Ludwig; Oskar A Haas; Giovanni Cazzaniga; Rolf Koehler; Daniela Silvestri; Jutta Bradtke; Rosanna Parasole; Rita Beier; Jacques J M van Dongen; Andrea Biondi; Martin Schrappe
Journal:  Blood       Date:  2010-02-12       Impact factor: 22.113

7.  Erdheim-Chester disease: a unique presentation with liver involvement and vertebral osteolytic lesions.

Authors:  Doina Ivan; Antonio Neto; Luciano Lemos; Arpan Gupta
Journal:  Arch Pathol Lab Med       Date:  2003-08       Impact factor: 5.534

Review 8.  Clinicopathologic features of histiocytic lesions following ALL, with a review of the literature.

Authors:  Eumenia C C Castro; Cristina Blazquez; Jaime Boyd; Hernán Correa; J-P de Chadarevian; Raymond E Felgar; Nicole Graf; Norman Levy; Eric J Lowe; John T Manning; Maria A Proytcheva; Christof Senger; Katayoon Shayan; Jaroslav Sterba; Alice Werner; Urvashi Surti; Ronald Jaffe
Journal:  Pediatr Dev Pathol       Date:  2010 May-Jun

9.  Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

Authors:  Charles G Mullighan; Letha A Phillips; Xiaoping Su; Jing Ma; Christopher B Miller; Sheila A Shurtleff; James R Downing
Journal:  Science       Date:  2008-11-28       Impact factor: 47.728

10.  CD2-positive B-cell precursor acute lymphoblastic leukemia with an early switch to the monocytic lineage.

Authors:  L Slamova; J Starkova; E Fronkova; M Zaliova; L Reznickova; F W van Delft; E Vodickova; J Volejnikova; Z Zemanova; K Polgarova; G Cario; M Figueroa; T Kalina; K Fiser; J P Bourquin; B Bornhauser; M Dworzak; J Zuna; J Trka; J Stary; O Hrusak; E Mejstrikova
Journal:  Leukemia       Date:  2013-11-25       Impact factor: 11.528
View more
  2 in total

1.  Independent development of lymphoid and histiocytic malignancies from a shared early precursor.

Authors:  E Waanders; K M Hebeda; E J Kamping; P J T A Groenen; A Simons; A Hoischen; M C J Jongmans; P M Hoogerbrugge; F N van Leeuwen; R P Kuiper; D M W M Te Loo
Journal:  Leukemia       Date:  2015-07-23       Impact factor: 11.528

2.  PAX5 P80R-mutated B-cell acute lymphoblastic leukemia with transformation to histiocytic sarcoma: clonal evolution assessment using NGS-based immunoglobulin clonality and mutation analysis.

Authors:  Leonie I Kroeze; B Scheijen; K M Hebeda; J Rijntjes; J A C W Luijks; D Evers; W Hobo; P J T A Groenen; M van den Brand
Journal:  Virchows Arch       Date:  2022-10-14       Impact factor: 4.535
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.